

REMARKS

The specification is amended as required to claim priority from the parent applications and the benefit of the Provisional Application.

The application is amended based on the restriction requirement imposed in the parent application. Applicants reserve the right to file additional applications drawn to additional non-elected subject matter.

Claims 1 and 13-14 are cancelled as being drawn to subject matter granted in the parent applications. Claims 15, 17 and 18 are cancelled since part of the subject matter of those claims (i.e., pharmaceutical compositions comprising any ORL-1 agonist and the method of treating cough with any ORL-1 agonist) is being pursued in a continuation-in-part application based on the grandparent application.

The claims comprising the group in the restriction requirement of the parent application directed to combinations of the novel compounds of the present invention and a second therapeutic agent are being pursued in this application. Therefore, new claim 19 was added to claim the method of treating cough with a combination of a novel compound of the invention (i.e., compounds of original claim 1) and a second therapeutic agent. Since the novel compounds of this invention are ORL-1 agonists, the subject matter of new claim 19 was included in original claim 18.

Similarly, claim 15 was cancelled and replaced with new claim 20, drawn to pharmaceutical compositions comprising novel ORL-1 agonists of this invention in combination with a second therapeutic agent. Since the novel compounds of this invention are ORL-1 agonists, the subject matter of new claim 20 was included in original claim 15.

Claims 2-12 were amended to be method of treatment claims in view of the replacement of claim 1 with new claim 19. The dependencies of claims 2-12 were amended as necessary so that the claims are dependent on new method claim 19 or the appropriate preceding claim. Claim 7 was also amended to correct a typographical error:  $\text{-NC(O)R}^{28}$  should have read  $\text{-NC(O)R}^{21}$ , since the definition

of  $X^2$  in claim 19 refers to the group  $-(CH_2)_vNHC(O)R^{21}$ , which corresponds to the amended group in claim 7 when  $v$  is 0.

No new matter has been introduced by the requested amendments.

Applicants look forward to an early examination on the merits.

Respectfully submitted,

1/21/04  
Date

Anita W. Magatti  
Reg. No. 29,825  
Attorney for Applicants  
(908) 298-5067